The majority of patients were receiving optimal medical therapy for heart failure, including angiotensin receptors–neprilysin inhibitors/angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (57%) and sodium–glucose cotransporter 2 (SGLT2) inhibitors (59.1%), with no significant differences between patients who developed RV reverse remodeling and those who did not. This evidence concerns the gene SLC5A2 and heart failure.